Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label Xeomin study in pediatric cerebral palsy spasticity
2012-005055-17Phase 3Completed
- Sponsor
- Merz
- Start
- Mar 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of botulinum toxin type A in cerebral palsy (CP) and spastic paresis, sponsored by Merz. Primary endpoint: Occurrence of treatment-emergent adverse events. Started Mar 2013; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
cerebral palsy (CP)spastic paresis
Beyond the preview
Go deeper on 2012-005055-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005055-17.